OVID Stock Analysis: Buy, Sell, or Hold?
OVID - Ovid Therapeutics Inc. Common Stock
$2.46
0.14 (5.82%)
▲
5d:
+4.03%
30d:
-0.61%
90d:
+1.45%
HOLD
MODERATE Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 12, 2026
Get Alerted When OVID Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: OVID shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: OVID shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: OVID is currently trading at $2.46, which is considered slightly high relative to its 30-day fair value range of $2.29 to $2.53.
Technical Outlook: Technically, OVID is in a strong uptrend. The price is approaching resistance at $2.51. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 5.8% recently.
Market Sentiment: OVID has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $5.47 (+135.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, OVID is in a strong uptrend. The price is approaching resistance at $2.51. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 5.8% recently.
Market Sentiment: OVID has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $5.47 (+135.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$2.29 -
$2.53
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
47.4%
All Signals
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+5.8%)
- BULLISH: Trading 135.8% below Wall St target ($5.47)
Trading Range Analysis
30-Day Trading Range
$2.29 -
$2.53
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$2.16
Resistance Level
$2.51
Current Trend
Strong Uptrend
Technical data as of
Jun 24, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-5.14
Wall Street Target
$5.47
(+135.8%)
Revenue Growth (YoY)
844.7%
Share & Embed Analysis
Last updated: June 24, 2026 1:11 PM ET
Data refreshes hourly during market hours. Next update: 2:11 PM
Data refreshes hourly during market hours. Next update: 2:11 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is OVID showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 54 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$31 | 62 BUY |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$122 | 55 HOLD |
|
DYN
Dyne Therapeutics Inc |
STRONG BUY
14 analysts |
$38 | 62 BUY |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
12 analysts |
$128 | 57 HOLD |
